A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
ACTFAST SWISS
A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
1 other identifier
interventional
370
1 country
20
Brief Summary
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2005
CompletedFirst Submitted
Initial submission to the registry
August 25, 2005
CompletedFirst Posted
Study publicly available on registry
August 29, 2005
CompletedFebruary 18, 2021
February 1, 2021
August 25, 2005
February 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Secondary Outcomes (1)
The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Interventions
Eligibility Criteria
You may qualify if:
- Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
- LDL-C \< 6.0 mmol/l
- Triglyceride level \< 5.0 mmol/l.
You may not qualify if:
- Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Pfizer Investigational Site
Binningen, Basel-Landschaft, Switzerland
Pfizer Investigational Site
Liestal, Basel-Landschaft, Switzerland
Pfizer Investigational Site
Basel, Canton of Basel-City, Switzerland
Pfizer Investigational Site
Langenthal, Canton of Bern, Switzerland
Pfizer Investigational Site
Thun, Canton of Bern, Switzerland
Pfizer Investigational Site
Düdingen, Canton of Fribourg, Switzerland
Pfizer Investigational Site
Geneva, Canton of Geneva, Switzerland
Pfizer Investigational Site
Onex, Canton of Geneva, Switzerland
Pfizer Investigational Site
Pfaeffikon, Canton of Schwyz, Switzerland
Pfizer Investigational Site
Siebnen, Canton of Schwyz, Switzerland
Pfizer Investigational Site
Écublens, Canton of Vaud, Switzerland
Pfizer Investigational Site
Lausanne, Canton of Vaud, Switzerland
Pfizer Investigational Site
Prilly, Canton of Vaud, Switzerland
Pfizer Investigational Site
Unterägeri, Canton of Zug, Switzerland
Pfizer Investigational Site
Zug, Canton of Zug, Switzerland
Pfizer Investigational Site
Zurich, Canton of Zurich, Switzerland
Pfizer Investigational Site
Lugano, Canton Ticino, Switzerland
Pfizer Investigational Site
Malvaglia, Canton Ticino, Switzerland
Pfizer Investigational Site
Melide, Canton Ticino, Switzerland
Pfizer Investigational Site
Vezia, Canton Ticino, Switzerland
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2005
First Posted
August 29, 2005
Study Start
April 1, 2005
Last Updated
February 18, 2021
Record last verified: 2021-02